Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $34.4 million.

  • 10x Genomics' Current Deferred Revenue rose 362.35% to $34.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $34.4 million, marking a year-over-year increase of 362.35%. This contributed to the annual value of $34.4 million for FY2025, which is 362.35% up from last year.
  • As of Q4 2025, 10x Genomics' Current Deferred Revenue stood at $34.4 million, which was up 362.35% from $33.0 million recorded in Q3 2025.
  • 10x Genomics' 5-year Current Deferred Revenue high stood at $34.4 million for Q4 2025, and its period low was $6.1 million during Q1 2021.
  • Over the past 5 years, 10x Genomics' median Current Deferred Revenue value was $15.8 million (recorded in 2023), while the average stood at $19.0 million.
  • As far as peak fluctuations go, 10x Genomics' Current Deferred Revenue surged by 10000.0% in 2024, and later skyrocketed by 362.35% in 2025.
  • Quarter analysis of 5 years shows 10x Genomics' Current Deferred Revenue stood at $7.7 million in 2021, then skyrocketed by 43.27% to $11.0 million in 2022, then soared by 99.42% to $22.0 million in 2023, then soared by 50.91% to $33.2 million in 2024, then increased by 3.62% to $34.4 million in 2025.
  • Its Current Deferred Revenue was $34.4 million in Q4 2025, compared to $33.0 million in Q3 2025 and $32.7 million in Q2 2025.